周五盘前，Organogenesis Holdings Inc（股票代码：ORGO）股价大跌7.08%，主要原因是公司公布的季度业绩低于市场预期。
根据公司最新发布的财报，截至6月30日的季度，Organogenesis调整后每股亏损0.10美元，显著低于分析师平均预期的0.06美元亏损。公司营收为1.0101亿美元，同比下降22.4%，同样未达到分析师预期的1.034亿美元。本季度，公司净亏损达1220万美元。这些数据反映了公司面临的经营压力，也解释了投资者对公司短期前景的担忧。
尽管季度业绩不佳导致股价大跌，但值得注意的是，Organogenesis的股价本季度仍上涨了23.0%，今年迄今为止更是上涨了40.6%。分析师对该公司仍持积极态度，目前平均评级为"买入"，12个月目标价中位数为7.00美元，较最近收盘价4.52美元高出约35.4%。这表明尽管短期面临挑战，但分析师仍看好公司的长期发展前景。投资者将密切关注公司未来的业绩表现，以评估其是否能够扭转当前的负面趋势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.